Type2 Diabetes

Metabolic Diseases
13
Pipeline Programs
14
Companies
15
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
3
7
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
250%
Monoclonal Antibody
125%
Peptide
125%
+ 12 programs with unclassified modality

On Market (3)

Approved therapies currently available

U
DAPAGLIFLOZINApproved
dapagliflozin
Unknown Company
AstraZeneca
FARXIGAApproved
dapagliflozin
AstraZeneca
oral2014
Regeneron
PRALUENTApproved
alirocumab
Regeneron
PCSK9 Inhibitor [EPC]injection2015

Competitive Landscape

14 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
2 programs
1
DPP-4 inhibitorPhase 41 trial
Peer Support Integrated with Primary CareN/A1 trial
Active Trials
NCT03958838Completed2,160Est. Nov 2021
NCT03813316Withdrawn0Est. Sep 2019
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
2
Insulin Degludec U100Phase 41 trial
Liraglutide Pen Injector [Victoza]Phase 4Peptide1 trial
Active Trials
NCT03349840Terminated273Est. Dec 2018
NCT03260881Completed38Est. Sep 2024
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
1
PRALUENT(Alirocumab)Phase 3Monoclonal Antibody2 trials
Active Trials
NCT03344692Completed22Est. Apr 2022
NCT02992301Unknown35Est. Nov 2019
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
DapagliflozinPhase 4Small Molecule1 trial
Active Trials
NCT02973477Completed45Est. Aug 2019
Catalyst Pharmaceuticals
Catalyst PharmaceuticalsCORAL GABLES, FL
1 program
1
BT-001Phase 31 trial
Active Trials
NCT05094401TerminatedEst. Apr 2023
Bristol Myers Squibb
1 program
1
DapagliflozinPhase 3Small Molecule
Plus Therapeutics
1 program
1
BioK+ 100% probioticPhase 21 trial
Active Trials
NCT03239366UnknownEst. Jun 2019
Neuraly
NeuralyMD - Gaithersburg
1 program
1
NLY01Phase 21 trial
Active Trials
NCT04159766CompletedEst. Dec 2020
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1
Stem Cells From Human Exfoliated TeethPhase 11 trial
Active Trials
NCT03658655CompletedEst. Nov 2019
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
Diabetes PuebloN/A1 trial
Active Trials
NCT04016584Completed25Est. Feb 2020
Insulet
InsuletACTON, MA
1 program
Omnipod 5 Automated Glucose Control SystemN/A1 trial
Active Trials
NCT05815342CompletedEst. Mar 2024
ME Therapeutics
ME TherapeuticsNEW YORK, NY
1 program
Phone-Based Health Coaching Utilizing Lifestyle Action PlansN/A
Beacon Therapeutics
Beacon TherapeuticsMA - Cambridge
1 program
Phone-Based Health Coaching Utilizing Lifestyle Action PlansN/A1 trial
Active Trials
NCT04872647UnknownEst. May 2021
Alliance Pharmaceuticals
1 program
Potato RegimenN/A1 trial
Active Trials
NCT04511325Completed27Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.DPP-4 inhibitor
Novo NordiskLiraglutide Pen Injector [Victoza]
Novo NordiskInsulin Degludec U100
AstraZenecaDapagliflozin
RegeneronAlirocumab
Catalyst PharmaceuticalsBT-001
RegeneronAlirocumab
NeuralyNLY01
Plus TherapeuticsBioK+ 100% probiotic
T-TherapeuticsStem Cells From Human Exfoliated Teeth
InsuletOmnipod 5 Automated Glucose Control System
Beacon TherapeuticsPhone-Based Health Coaching Utilizing Lifestyle Action Plans
Eli Lilly and CompanyDiabetes Pueblo
Alliance PharmaceuticalsPotato Regimen
Merck & Co.Peer Support Integrated with Primary Care

Clinical Trials (15)

Total enrollment: 2,625 patients across 15 trials

NCT03813316Merck & Co.DPP-4 inhibitor

Approaches To Therapy Escalation In T2D

Start: May 2019Est. completion: Sep 20190
Phase 4Withdrawn
NCT03260881Novo NordiskLiraglutide Pen Injector [Victoza]

Liraglutide Effects on Epicardial Fat Inflammatory Genes

Start: Sep 2018Est. completion: Sep 202438 patients
Phase 4Completed
NCT03349840Novo NordiskInsulin Degludec U100

Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan

Start: Jan 2018Est. completion: Dec 2018273 patients
Phase 4Terminated
NCT02973477AstraZenecaDapagliflozin

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

Start: Jan 2017Est. completion: Aug 201945 patients
Phase 4Completed
NCT02992301RegeneronAlirocumab

Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab

Start: Nov 2016Est. completion: Nov 201935 patients
Phase 4Unknown
NCT05094401Catalyst PharmaceuticalsBT-001

Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes

Start: Oct 2021Est. completion: Apr 2023
Phase 3Terminated
NCT03344692RegeneronAlirocumab

Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes

Start: Feb 2019Est. completion: Apr 202222 patients
Phase 3Completed
NCT04159766NeuralyNLY01

A Study With NLY01 in Subjects With Type 2 Diabetes

Start: Oct 2019Est. completion: Dec 2020
Phase 2Completed
NCT03239366Plus TherapeuticsBioK+ 100% probiotic

A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population

Start: Sep 2017Est. completion: Jun 2019
Phase 2Unknown
NCT03658655T-TherapeuticsStem Cells From Human Exfoliated Teeth

Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes

Start: Jun 2018Est. completion: Nov 2019
Phase 1Completed
NCT05815342InsuletOmnipod 5 Automated Glucose Control System

OP5-005 Using Omnipod 5 in Adults With Type 2

Start: Apr 2023Est. completion: Mar 2024
N/ACompleted
NCT04872647Beacon TherapeuticsPhone-Based Health Coaching Utilizing Lifestyle Action Plans

Pilot of Virtual Health Coaching Utilizing Lifestyle for Under-Resourced Patients With Type II Diabetes

Start: Dec 2020Est. completion: May 2021
N/AUnknown
NCT04016584Eli Lilly and CompanyDiabetes Pueblo

Diabetes Pueblo Program - Application and Acceptability of Culturally Appropriate Latino Education for Insulin Therapy

Start: May 2019Est. completion: Feb 202025 patients
N/ACompleted
NCT04511325Alliance PharmaceuticalsPotato Regimen

Effects of White Potato Consumption on Measures of Cardiometabolic Health in Individuals With Type 2 Diabetes Mellitus

Start: Apr 2019Est. completion: May 202227 patients
N/ACompleted
NCT03958838Merck & Co.Peer Support Integrated with Primary Care

Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities

Start: Mar 2019Est. completion: Nov 20212,160 patients
N/ACompleted

Related Jobs in Metabolic Diseases

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
20h ago

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
Yesterday

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Senior Specialist, Quality Management Systems

Crinetics Pharmaceuticals
San Diego, CA
4d ago
$91K - $114K/yr

Director, Quality Systems, Project Management, QRM, RS

Crinetics Pharmaceuticals
US California
4d ago
$178K - $223K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
14 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)